Use of Recombinant Human Growth Hormone in Alveolar Ridge Preservation Procedures: A Case Report
L. Zanettini,R. Marco,Fern,O. D. O. Andriola,O. Antonini,H. Oliveira,R. Mir,A. Pagnoncelli
DOI: https://doi.org/10.15406/JDHODT.2017.08.00293
2017-10-17
Abstract:Submit Manuscript | http://medcraveonline.com [1-3]. Studies show that the most severe resorption occurs in the first 3 months of healing, although dimensional changes can be observed after one year of tooth extraction, resulting in a reduction of approximately 50% in the buccal-lingual / palatal dimension of the alveolus [4]. The clinical consequences of these physiological tissue changes may affect the results of therapies used to restore lost dentition, limiting the optimal bone quantity for implant placement or even compromising aesthetic results for prosthesis rehabilitation. Different therapies of alveolar preservation were proposed, such as: minimally invasive surgeries, without flaps; Dental extractions and immediate implants; filling the alveolus with different types of graft materials, with or without membrane [5]. Alveolar preservation therapies were proposed with the objective of maintaining the dimensions of alveolar bone tissue, which would be lost after the dental extraction procedures, as part of a natural physiological process of healing. The purpose of these therapies is to prepare the bone site for the placement of osseointegrated implants, in order to have a viable bone for rehabilitation [6]. Recombinant Human Growth Hormone (RhGh) has been studied in cases of dental implants [7], use in TMJ pathologies, and bone fractures [8,9]. Human Growth Hormone is produced by the anterior pituitary gland and has an effect on all cells of the body, increasing the speed of protein synthesis, increasing the consumption of fatty acids and reducing the speed of glucose consumption. In this way, it preserves carbohydrates, consumes reserves of energy and increases the deposition of proteins, including the chondrocytic and osteogenic cells [10]. RhGH is capable of stimulating bone growth in a dose-dependent manner by direct stimulation of chondrocytes. It stimulates the proliferation and differentiation of chondroprogenitor cells. It also acts directly on osteoblasts, increasing remodeling rates and bone formation [11]. Based on the above evidence, the purpose of this article was to report a case using Recombinant Human Growth Hormone in post-extraction alveolar preservation procedures, in order to evaluate the benefits of this technique, which is promising to maintain the post-extraction bone site viable, aiming the future rehabilitation with dental implants and prostheses.